On 10 JUNE Arrowhead Research Corp (NASDAQ:ARWR) announced that it will present at two upcoming investor conferences. Scheduled presentations include the following: Wells Fargo 2014 Healthcare Conference – Boston June 17, 2014 – At 1:45 p.m. EDT Christopher Anzalone, Ph.D., President and Chief Executive Officer, will deliver a corporate presentation, and at 2:20 p.m. EDT he will participate in the “Gene Manipulation” panel discussion. Piper Jaffray GenomeRx Symposium – New York. June 23, 2014 – At 3:30 p.m. EDT David Lewis, Ph.D., Chief Scientific Officer, will participate in the “RNA/DNA: Getting It Where You Need It” panel discussion. Arrowhead Research Corp (NASDAQ:ARWR) weekly performance is -13.23%. On last trading day company shares ended up $12.33. Analysts mean target price for the company is $27.90. Arrowhead Research Corp (NASDAQ:ARWR) distance from 50-day simple moving average (SMA50) is -3.40%.
On 15 MAY Eleven Biotherapeutics Inc (NASDAQ:EBIO) reported financial results for the quarter ended March 31 2014. Revenues were $0.6 million during the quarter ended March 31, 2014 compared to $0 for the quarter ended March 31, 2013 and include amounts from the Thrombogenics collaboration which began in May 2013. Eleven Biotherapeutics Inc (NASDAQ:EBIO) shares fell -7.84% in last trading session and ended the day on $10.81. EBIO return on assets is -444.80%. Eleven Biotherapeutics Inc (NASDAQ:EBIO) quarterly performance is -36.60%.
On 29 MAY Concert Pharmaceuticals Inc (NASDAQ:CNCE) reported ($0.76) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by $0.27. The company had revenue of $1.61 million for the quarter, compared to the consensus estimate of $0.44 million. The company’s revenue for the quarter was down 59.0% on a year-over-year basis. Analysts expect that Concert Pharmaceuticals will post $-1.29 EPS for the current fiscal year. Concert Pharmaceuticals Inc (NASDAQ:CNCE) shares moved down -6.24% in last trading session and was closed at $8.87, while trading in range of $8.86 – $10.00. Concert Pharmaceuticals Inc (NASDAQ:CNCE) year to date (YTD) performance is -37.45%.
Oncomed Pharmaceuticals Inc (NASDAQ:OMED) announced that it has voluntarily halted patient enrollment and dosing in its ongoing Phase 1 clinical trials of its two Wnt pathway inhibitor programs, vantictumab and Fzd8-Fc. Oncomed Pharmaceuticals Inc (NASDAQ:OMED) ended the last trading day at $22.71. Company weekly volatility is calculated as 9.56% and price to cash ratio as 2.36. Oncomed Pharmaceuticals Inc (NASDAQ:OMED) showed a negative weekly performance of -4.90%.
On 6 JUNE Pain Therapeutics, Inc. (NASDAQ:PTIE) reported ($0.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by $0.02. During the same quarter in the previous year, the company posted ($0.01) earnings per share. Analysts expect that Pain Therapeutics will post $-0.30 EPS for the current fiscal year. Pain Therapeutics, Inc. (NASDAQ:PTIE) net profit margin is 76.60%and weekly performance is 4.00%. On last trading day company shares ended up $5.20. Analysts mean target price for the company is $8.00. Pain Therapeutics, Inc. (NASDAQ:PTIE) distance from 50-day simple moving average (SMA50) is -0.22%.